It's day three of the Pfizer-Sanofi merger watch. Sanofi-Aventis shares are up 5.5 percent on continued rumors of a Pfizer investment in its business. Now, experts are saying that a Sanofi acquisition wouldn't be prudent for Pfizer--but a partnership would.
If Pfizer just bought a stake in Sanofi, it could share in the French company's revenues. Sanofi would get access to Pfizer's U.S. sales force [1]. And the companies wouldn't have to get the French government's blessing on this sort of deal--a blessing that might be hard to come by.
- read the report [2] from Fortune
Related Articles:
Pfizer-Sanofi match not made in heaven? Report [3]
Sanofi stock up on Pfizer buyout talk. Report [4]
Pfizer, Wyeth merger bad idea? Report [5]
Read more on: Pfizer [6]Â | Sanofi-Aventis [7]
Links:
[1] http://www.fiercebiotech.com/story/pfizer-to-axe-2200-sales-jobs-in-realignment/2006-11-29
[2] http://money.cnn.com/2007/10/10/magazines/fortune/simons_sanofi.fortune/index.htm?postversion=2007101012
[3] http://www.fiercepharma.com/story/pfizer-sanofi-match-not-made-heaven/2007-10-10
[4] http://www.fiercepharma.com/story/sanofi-stock-up-on-pfizer-buyout-talk/2007-10-09?utm_medium=nl&utm_source=link
[5] http://www.fiercepharma.com/story/pfizer-wyeth-merger-bad-idea/2007-08-27
[6] http://www.fiercebiotech.com/tags/pfizer
[7] http://www.fiercebiotech.com/tags/sanofi-aventis